AstraZeneca Confident of Reaching $45bn Sales by 2023

AstraZeneca have confirmed that they remain confident of generating annual sales of over $45 billion by 2023. The increase is expected as a result of accelerating growth momentum from both AstraZeneca’s existing products and those currently awaiting market approval. Five current growth platforms (diabetes, Brilinta, respiratory, Emerging Markets and Japan) currently account for over half

Continue Reading

AstraZeneca Acquires Definiens

AstraZeneca has announced that they are acquiring tissue sample specialist, Definiens, increasing their oncology efforts. AstraZeneca’s MedImmune unit is paying an initial $150 million, followed by additional predetermined milestone payments, to acquire Definiens.  AstraZeneca noted that Definiens has “pioneered a world-leading imaging and data analysis technology, known as Tissue Phenomics, which dramatically improves the identification

Continue Reading

Bristol-Myers Squibb Announce Positive Q3 Results

Bristol-Myers Squibb have announced positive third quarter results for 2014, beating earlier forecasts after stronger-than-expected revenues for the period. The biopharmaceutical company posted earnings on Friday of $721 million, or $0.43 a share, an increase from earnings of $692 million, or $0.42 per share, in Q3 of 2013.  Once adjusted for special items, Bristol-Myers Squibb’s

Continue Reading

Roche Reports Positive Q3 2014 Results

Roche has announced positive Q3 results for 2014, with pharmaceutical sales increasing by 4% in the third quarter to 9.13bn francs, while their diagnostics division grew by 7% to 2.65bn francs. The results were boosted by increased sales of Roche’s new breast cancer drugs, Perjeta and Kadcyla.  Sales of Perjeta more than tripled to reach

Continue Reading

Bayer to Increase Pharmaceutical R&D Spend

Bayer have announced additional details on the future of their pharmaceutical research and development business following the announcement earlier this week that they will be concentrating on their healthcare and crop science businesses going forward. The announcement confirmed Bayer plans to float their material science division on the stock market and focus on life sciences,

Continue Reading

Janssen’s Affiliate Cilag to Acquire Covagen

Janssen affiliate’s Cilag GmbH International has announced that they will be acquiring Swiss biotech Covagen AG for an undisclosed sum. The purchase was finalised in a deal brokered by Johnson & Johnson Innovation Center in London. Covagen specialises in the development of multi-specific protein therapeutics through their FynomAb technology platform, which binds proteins to antibodies,

Continue Reading

Reckitt to Spinoff their Pharmaceutical Business

Reckitt Benckiser have today announced that they are planning on separating their pharmaceutical business, as they continue to concentrate on consumer health and hygiene. The process to separate RB Pharmaceuticals to be a separate UK listing is expected to occur within the next 12 months. The decision was founded from Reckitt’s belief that the division

Continue Reading

Positive Clinical Trial Results for Bristol-Myers Squibb’s Immunotherapy Combo

Results of a clinical trial combining Bristol-Myers Squibb’s Yervoy and Nivolumab show an exceptional improvement in tumour regression and overall survival rate for patients with advanced melanoma. Mario Sznol of Yale University School of Medicine, reporting the results of the early-stage study, commented that “this is the first trial conducted with this combination in melanoma.” 

Continue Reading

Bristol-Myers Squibb Announce Oncology Research Collaborations with CytomX and Incyte

Bristol-Myers Squibb (B-MS) yesterday announced a worldwide research partnership and license agreement with CytomX. The collaboration plans to discover, develop and commercialise novel therapies against multiple immuno-oncology targets using CytomX’s proprietary Probody Platform. Probodies are monoclonal antibodies selectively activated within the cancer microenvironment, to focus the activity of therapeutic antibodies to tumours and helping spare

Continue Reading